Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis

Clinical and Translational Oncology

Volumn 11, Issue 4, 2009, Pages 243-249

  Kocdor, Hilal ^a   Kocdor, Mehmet Ali ^a   Canda, Tulay ^a   Gurel, Duygu ^a   Cehreli, Ruksan ^a   Yilmaz, Osman ^a   Alakavuklar, Mehmet ^a   Guner, Gul ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Chemoprevention; DMBA; Fenretinide; Mammary carcinogenesis; Rosiglitazone

Indexed keywords

FENRETINIDE; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN; ESTRADIOL; PROLACTIN; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; IN VIVO STUDY; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; METABOLISM; PATHOLOGY;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FENRETINIDE; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, EXPERIMENTAL; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 67650224995     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0347-5     Document Type: Article

References (44)

1. Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: The second decade. Cell 83:835-839
2. Aranda A, Pascual A (2001) Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304
3. Shen Q, Brown PH (2003) Novel agents for the prevention of breast cancer: Targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 8:45-73
4. Lotan R (1996) Retinoids in cancer chemoprevention. FASEB J 10:1031-1039
5. Hansen LA, Sigman CC, Andreola F et al (2000) Retinoids and chemoprevention and differentiation therapy. Carcinogenesis 21:1271-1279
6. DeLuca LM (1991) Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 5:2924-2933
7. Zusi FC, Lorenzi MV, Vivat-Hannah V (2002) Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov Today 7:1165-1174
8. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193
9. Sabichi AL, Xu H, Fischer S et al (2003) Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 9:4606-4613
10. Sun SY, Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41:41-55
11. Simeone AM, Tari AM (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61:1475-1484
12. Lippman SM, Lotan R (2000) Advances in the development of retinoids as chemopreventive agents. J Nutr 130:479S-482S
13. Roberts-Thompson SJ (2000) Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment. Immunol Cell Biol 78:436-441
14. Koeffner HP (2003) Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 9:1-9
15. Pighetti GM, Novosad W, Nicholson C et al (2001) Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res 21:825-829
16. Elstner E, Müller C, Koshizuka K et al (1998) Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci 95:8806-8811
17. Mehta RG, Williamson E, Patel MK, Koeffner HP (2000) A ligand of peroxisome proliferator-activated receptor-γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92:418-423
18. Szanto A, Nagy L (2005) Retinoids potentiate PPAR-γ action in differentiation, gene expression and lipid metabolic processes in developing myeloid cells. Mol Pharmacol 67:1935-1943
19. Elstner E, Williamson EA, Zang C et al (2002) Novel therapeutic approach: Ligands for PPAR-gamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 74:155-165
20. Serrano D, Perego E, Costa A, Decensi A (2004) Progress in chemoprevention of breast cancer. Crit Rev Oncol Hematol 49:109-117
21. Torrisi R, Decensi A, Formelli F et al (2001) Chemoprevention of breast cancer with fenretinide. Drugs 61:909-918
22. Wu JM, DiPietrantonio AM, Hsieh TC (2003) Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 6:377-388
23. Dmitrovsky E (2004) Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst 96:1264-1265
24. Renehan AG, Egger M, Minder C et al (2005) IGF-1, IGF binding protein-3 and breast cancer risk: Comparison of 3 meta-analyses. Int J Cancer 115:1006-1007
25. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor I receptor signalling in cancer. Br J Cancer 92:2097-2101
26. Pollak M (2000) Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224-1228
27. Mehta RG (2000) Experimental basis for the prevention of breast cancer. Eur J Cancer 36:1275-1282
28. Umrani DN, Banday AA, Hussain T, Lokhandwala MF (2002) Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension 40:880-885
29. Cardiff RD, Anver MR, Gusterson BA et al (2000) The mammary pathology of genetically engineered mice: The consensus report and recommendations from Annapolis meeting. Oncogene 19:968-988
30. Prochazkova J, Kylarova D, Vranka P, Lichnosky V (2003) Comparative study of apoptosis-detecting techniques: TUNEL, apostain and lamin B. Biotechniques 35:528-534
31. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L (2000) Monoclonal antibody to single-strand DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res 226:387-397
32. McCormick DL, Burns FJ, Albert RE (1980) Inhibition of rat mammary carcinogenesis by short dietary exposure to retinyl acetate. Cancer Res 40:1140-1143
33. Harris G, Ghazallah RA, Nascene D et al (2005) PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg 133:695-701
34. Peng X, Wood S, Bratescu L et al (2005) Retinoids suppress premalignant MCF10AT but not malignant MCF10CA1a breast epithelial cells in vivo. Role of retinoic acid receptor β2 expression. Cancer Lett 222:153-163
35. Green A, Shilkaitis A, Christov K (1999) 4-(Hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. Carcinogenesis 20:1535-1540
36. Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49-61
37. Russo IH, Russo J (2007) Primary prevention of breast cancer by hormone-induced differentiation. Recent Results Cancer Res 174:111-130
38. Russo J, Russo IH (2004) Development of human breast. Maturitas 49:2-15
39. Russo J, Mailo D, Hu YF et al (2005) Breast differentiation and implication in cancer prevention. Clin Cancer Res 11:931s-936s
40. Thompson HJ, Singh M (2000) Rat models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:409-420
41. Heaney AP, Fernando M, Melmed S (2003) PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
42. Fürstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3:298-302
43. Renehan AG, Zwahlen M, Minder C et al (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 9418:1346-1353
44. Torrisi R, Parodi S, Fontana V et al (1998) Effect of fenretinide on plasma IGF-1 and IGFBP-3 in early breast cancer patients. Int J Cancer 76:787-790